1
|
Goff DC: The pharmacologic treatment of
schizophrenia-2021. JAMA. 325:175–176. 2021.PubMed/NCBI View Article : Google Scholar
|
2
|
Goff DC, Falkai P, Fleischhacker WW,
Girgis RR, Kahn RM, Uchida H, Zhao J and Lieberman JA: The
long-term effects of antipsychotic medication on clinical course in
schizophrenia. Am J Psychiatry. 174:840–849. 2017.PubMed/NCBI View Article : Google Scholar
|
3
|
Middeldorp CM, Cath DC, Van Dyck R and
Boomsma DI: The co-morbidity of anxiety and depression in the
perspective of genetic epidemiology. A review of twin and family
studies. Psychol Med. 35:611–624. 2005.PubMed/NCBI View Article : Google Scholar
|
4
|
Pardiñas AF, Owen MJ and Walters JTR:
Pharmacogenomics: A road ahead for precision medicine in
psychiatry. Neuron. 109:3914–3929. 2021.PubMed/NCBI View Article : Google Scholar
|
5
|
Biso L, Aringhieri S, Carli M, Scarselli M
and Longoni B: Therapeutic drug monitoring in psychiatry: Enhancing
treatment precision and patient outcomes. Pharmaceuticals (Basel).
17(642)2024.PubMed/NCBI View Article : Google Scholar
|
6
|
Phillips KA, Veenstra DL, Oren E, Lee JK
and Sadee W: Potential role of pharmacogenomics in reducing adverse
drug reactions: A systematic review. JAMA. 286:2270–2279.
2001.PubMed/NCBI View Article : Google Scholar
|
7
|
Solomon HV, Cates KW and Li KJ: Does
obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict
antidepressant response or adverse drug reactions? Psychiatry Res.
271:604–613. 2019.PubMed/NCBI View Article : Google Scholar
|
8
|
Chaplin M, Kirkham JJ, Dwan K, Sloan DJ,
Davies G and Jorgensen AL: STrengthening the reporting of
pharmacogenetic studies: Development of the STROPS guideline. PLoS
Med. 17(e1003344)2020.PubMed/NCBI View Article : Google Scholar
|
9
|
Verbelen M, Weale ME and Lewis CM:
Cost-effectiveness of pharmacogenetic-guided treatment: Are we
there yet? Pharmacogenomics J. 17:395–402. 2017.PubMed/NCBI View Article : Google Scholar
|
10
|
Leitch TM, Killam SR, Brown KE, Katseanes
KC, George KM, Schwanke C, Loveland J, Elias AF, Haney K, Krebsbach
K, et al: Ensuring equity: Pharmacogenetic implementation in rural
and tribal communities. Front Pharmacol. 13(953142)2022.PubMed/NCBI View Article : Google Scholar
|
11
|
Kloosterboer SM, Egberts KM, de Winter
BCM, van Gelder T, Gerlach M, Hillegers MHJ, Dieleman GC, Bahmany
S, Reichart CG, van Daalen E, et al: Pipamperone population
pharmacokinetics related to effectiveness and side effects in
children and adolescents. Clin Pharmacokinet. 59:1393–1405.
2020.PubMed/NCBI View Article : Google Scholar
|
12
|
Hassab Errasoul A and Alarabi MA: Factors
predicting serum clozapine levels in Middle Eastern patients: An
observational study. BMC Psychiatry. 22(269)2022.PubMed/NCBI View Article : Google Scholar
|
13
|
Sun L, von Moltke L and Rowland Yeo K:
Application of physiologically based pharmacokinetic modeling to
predict the effect of renal impairment on the pharmacokinetics of
olanzapine and samidorphan given in combination. Clin
Pharmacokinet. 60:637–647. 2021.PubMed/NCBI View Article : Google Scholar
|
14
|
Li XL, Huang SQ, Xiao T, Wang XP, Kong W,
Liu SJ, Zhang Z, Yang Y, Huang SS, Ni XJ, et al: Pharmacokinetics
of immediate and sustained-release formulations of paroxetine:
Population pharmacokinetic approach to guide paroxetine
personalized therapy in chinese psychotic patients. Front
Pharmacol. 13(966622)2022.PubMed/NCBI View Article : Google Scholar
|
15
|
Lin S, Zhu N, YihanZhang Du L and Zhang S:
Development and validation of a prediction model of
catheter-related thrombosis in patients with cancer undergoing
chemotherapy based on ultrasonography results and clinical
information. J Thromb Thrombolysis. 54:480–491. 2022.PubMed/NCBI View Article : Google Scholar
|
16
|
Jin H, Shen X, Song W, Liu Y, Qi L and
Zhang F: The development of nomograms to predict blastulation rate
following cycles of in vitro fertilization in patients with tubal
factor infertility, polycystic ovary syndrome, or endometriosis.
Front Endocrinol (Lausanne). 12(751373)2021.PubMed/NCBI View Article : Google Scholar
|
17
|
Chen C and Lu FC: Department of Disease
Control Ministry of Health, PR China. The guidelines for prevention
and control of overweight and obesity in Chinese adults. Biomed
Environ Sci. 17 (Suppl):S1–S36. 2004.PubMed/NCBI
|
18
|
National Health Commission of the People's
Republic of China: WS/T 404.1-2012 Reference Intervals for Common
Clinical Biochemical Tests-Part 1. China Standards Press, Beijing,
2012.
|
19
|
National Health Commission of the People's
Republic of China: WS/T 404.2-2012 Reference Intervals for Common
Clinical Biochemical Tests-Part 2. China Standards Press, Beijing,
2012.
|
20
|
National Health Commission of the People's
Republic of China: WS/T 404.4-2012 Reference Intervals for Common
Clinical Biochemical Tests-Part 4. China Standards Press, Beijing,
2012.
|
21
|
National Health Commission of the People's
Republic of China: WS/T 404.6-2012 Reference Intervals for Common
Clinical Biochemical Tests-Part 6. China Standards Press, Beijing,
2012.
|
22
|
Rajman I, Knapp L, Morgan T and
Masimirembwa C: African genetic diversity: Implications for
cytochrome P450-mediated drug metabolism and drug development.
EBioMedicine. 17:67–74. 2017.PubMed/NCBI View Article : Google Scholar
|
23
|
Song C, Yu D, Wang Y, Wang Q, Guo Z, Huang
J, Li S and Hu W: Dual primary cancer patients with lung cancer as
a second primary malignancy: A population-based study. Front Oncol.
10(515606)2020.PubMed/NCBI View Article : Google Scholar
|
24
|
Wang S, Tian S, Li Y, Zhan N, Guo Y, Liu
Y, Xu J, Ma Y, Zhang S, Song S, et al: Development and validation
of a novel scoring system developed from a nomogram to identify
malignant pleural effusion. EBioMedicine. 58(102924)2020.PubMed/NCBI View Article : Google Scholar
|
25
|
Lozupone M, Panza F, Stella E, La Montagna
M, Bisceglia P, Miscio G, Galizia I, Daniele A, di Mauro L, Bellomo
A, et al: Pharmacogenetics of neurological and psychiatric diseases
at older age: Has the time come? Expert Opin Drug Metab Toxicol.
13:259–277. 2017.PubMed/NCBI View Article : Google Scholar
|
26
|
Gomez A and Ingelman-Sundberg M:
Epigenetic and microRNA-dependent control of cytochrome P450
expression: A gap between DNA and protein. Pharmacogenomics.
10:1067–1076. 2009.PubMed/NCBI View Article : Google Scholar
|
27
|
Seripa D, Panza F, Daragjati J, Paroni G
and Pilotto A: Measuring pharmacogenetics in special groups:
Geriatrics. Expert Opin Drug Metab Toxicol. 11:1073–1088.
2015.PubMed/NCBI View Article : Google Scholar
|
28
|
Bies RR, Feng Y, Lotrich FE, Kirshner MA,
Roose S, Kupfer DJ and Pollock BG: Utility of sparse concentration
sampling for citalopram in elderly clinical trial subjects. J Clin
Pharmacol. 44:1352–1359. 2004.PubMed/NCBI View Article : Google Scholar
|
29
|
Dhillon S, Scott LJ and Plosker GL:
Escitalopram: A review of its use in the management of anxiety
disorders. CNS Drugs. 20:763–790. 2006.PubMed/NCBI View Article : Google Scholar
|
30
|
Jin Y, Pollock BG, Frank E, Cassano GB,
Rucci P, Müller DJ, Kennedy JL, Forgione RN, Kirshner M, Kepple G,
et al: Effect of age, weight, and CYP2C19 genotype on escitalopram
exposure. J Clin Pharmacol. 50:62–72. 2010.PubMed/NCBI View Article : Google Scholar
|
31
|
Kirchheiner J, Nickchen K, Bauer M, Wong
ML, Licinio J, Roots I and Brockmöller J: Pharmacogenetics of
antidepressants and antipsychotics: The contribution of allelic
variations to the phenotype of drug response. Mol Psychiatry.
9:442–473. 2004.PubMed/NCBI View Article : Google Scholar
|
32
|
Richards-Belle A, Austin-Zimmerman I, Wang
B, Zartaloudi E, Cotic M, Gracie C, Saadullah Khani N,
Wannasuphoprasit Y, Wronska M, Dawda Y, et al: Associations of
antidepressants and antipsychotics with lipid parameters: Do
CYP2C19/CYP2D6 genes play a role? A UK population-based study. J
Psychopharmacol. 37:396–407. 2023.PubMed/NCBI View Article : Google Scholar
|
33
|
Zanger UM and Schwab M: Cytochrome P450
enzymes in drug metabolism: Regulation of gene expression, enzyme
activities, and impact of genetic variation. Pharmacol Ther.
138:103–141. 2013.PubMed/NCBI View Article : Google Scholar
|
34
|
Austin-Zimmerman I, Wronska M, Wang B,
Irizar H, Thygesen JH, Bhat A, Denaxas S, Fatemifar G, Finan C,
Harju-Seppänen J, et al: The influence of CYP2D6 and CYP2C19
genetic variation on diabetes mellitus risk in people taking
antidepressants and antipsychotics. Genes (Basel).
12(1758)2021.PubMed/NCBI View Article : Google Scholar
|
35
|
Hägg S, Spigset O and Dahlqvist R:
Influence of gender and oral contraceptives on CYP2D6 and CYP2C19
activity in healthy volunteers. Br J Clin Pharmacol. 51:169–173.
2001.PubMed/NCBI View Article : Google Scholar
|
36
|
Meibohm B, Beierle I and Derendorf H: How
important are gender differences in pharmacokinetics? Clin
Pharmacokinet. 41:329–342. 2002.PubMed/NCBI View Article : Google Scholar
|
37
|
Maatouk I, Herzog W, Böhlen F, Quinzler R,
Löwe B, Saum KU, Brenner H and Wild B: Association of hypertension
with depression and generalized anxiety symptoms in a large
population-based sample of older adults. J Hypertens. 34:1711–1720.
2016.PubMed/NCBI View Article : Google Scholar
|
38
|
Castberg I, Westin AA, Skogvoll E and
Spigset O: Effects of age and gender on the serum levels of
clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr
Scand. 136:455–464. 2017.PubMed/NCBI View Article : Google Scholar
|
39
|
Shah RR: Drug development and use in the
elderly: Search for the right dose and dosing regimen (parts I and
II). Br J Clin Pharmacol. 58:452–469. 2004.PubMed/NCBI View Article : Google Scholar
|
40
|
Black CN, Bot M, Scheffer PG, Cuijpers P
and Penninx BW: Is depression associated with increased oxidative
stress? A systematic review and meta-analysis.
Psychoneuroendocrinology. 51:164–175. 2015.PubMed/NCBI View Article : Google Scholar
|
41
|
Chaudhari K, Khanzode S, Khanzode S,
Dakhale G, Saoji A and Sarode S: Clinical correlation of alteration
of endogenous antioxidant-uric acid level in major depressive
disorder. Indian J Clin Biochem. 25:77–81. 2010.PubMed/NCBI View Article : Google Scholar
|